Board of
Directors

Board of
Directors

Thomas Gad (Chairman) is Founder, President, and Head of Business Development and Strategy. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience receiving breakthrough immunotherapy at Memorial Sloan Kettering Cancer Center (MSKCC) to overcome the cancer, Mr. Gad founded Y-mAbs Therapeutics, securing executive management and seed capital for the inception of the Company. Mr. Gad has more than 12 years of experience in the pharmaceutical industry, including business development, senior management, financing, and licensing negotiations. Mr. Gad has a Bachelor of Science degree in Business Administration from Pepperdine University, California, US.

Claus Moller, MD, PhD, serves as Chief Executive Officer of the Company. Dr. Moller is the Founder of Azanta A/S and was the Chief Executive Officer of Azanta from 2009 to 2015. In addition, Dr. Moller has extensive experience in the pharmaceutical and biotechnology industries and was a co-founder of one of the largest European biotech companies, Genmab A/S, in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Previous positions include Executive Vice President and Chief Medical and Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Dr. Moller received his MD and PhD degrees from the University of Copenhagen, Denmark.

Johan Wedell-Wedellsborg is Owner and Chairman of the Board of Weco Group, which he took over in 2001. Weco Group is primarily a Ship Owning Company, which operates within the product tanker segment, multi-purpose vessels, RORO line and handy size bulk carriers. The shipping part of Weco Group records annual revenue of approximately $200 million. Besides shipping, Weco Group also is involved in realty investments, financial services, art and biotech. Wedell-Wedellsborg is educated within shipping in Hamburg, Germany and has also worked out of London in the United Kingdom and Houston, Texas.

Gérard Ber has more than 30 years of experience in Molecular Nuclear Medicine (MNM). In 2002, Dr. Ber co-founded Advanced Accelerator Applications S.A., and was its Chief Operating Officer from 2002 to 2018, when it was sold to Novartis AG. Dr. Ber grew Advanced Accelerator Applications from a start-up to a global leader in MNM and was a member of its Board of Directors from 2002 to 2015, when Advanced Accelerator Applications listed on the Nasdaq Global Select Market. He received his PhD degree in Pharmacy from the Scientific and Medical University of Grenoble.

Ashutosh Tyagi, M.D. has been a member of our Board of Directors since November 2017, representing until the end of 2018 Scopia Capital Management LP, or Scopia Capital, an institutional alternative asset management firm. Dr. Tyagi was with Scopia Capital from 2010 to 2018 (as a partner from 2012 to 2018). At Scopia Capital, Dr. Tyagi managed global health care investments and was a Co-Portfolio Manager of Scopia Capital’s health care funds. Prior to joining Scopia, he worked at Lombard Odier, Morgan Stanley, and Citigroup. Dr. Tyagi received a B.A. in Asian Studies from the University of Michigan, an MBA from the University of Michigan Business School and an M.D. from the University of Michigan School of Medicine.

James I. Healy, MD, PhD, has been a General Partner at Sofinnova Ventures, Inc., since 2000. Prior to this role, Dr. Healy held various positions at Bayer HealthCare Pharmaceuticals, Inc., Sanderling Ventures, and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the Board of Directors of Ascendis Pharma A/S, Coherus BioSciences, Inc., Edge Therapeutics, Inc., ObsEva SA, Natera, Inc., NuCana plc, and several other private companies. Previously, Dr. Healy served as a board member for Amarin Corporation plc, Anthera Pharmaceuticals, Inc., Auris Medical Holding AG, Durata Therapeutics, Inc., Hyperion Therapeutics, Inc., InterMune, Inc., KaloBios Pharmaceuticals, Inc., and Movetis NV, in addition to a number of private companies. Dr. Healy holds a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California, Berkeley, and an MD and a PhD in Immunology from Stanford University School of Medicine, California.

David N. Gill has over 30 years’ experience in senior operating and financial roles in the life sciences industry. He was most recently the President and Chief Financial Officer of EndoChoice Holdings, Inc., a publicly traded medical device company focused on gastroenterology products that was acquired in November 2016. Prior to EndoChoice he was the Chief Financial Officer of INC Research from 2011 to 2013 after having served as an independent board member from 2007 through 2010. INC Research (now known as Syneos) is a large, global clinical research organization (CRO) which provides outsourced pharmaceutical development services on a global basis. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical Systems. He currently serves as a director of the following public companies: Y-mAbs Therapeutics, Evolus and Strongbridge Biopharma.

Laura J. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees and $22 billion in annual revenue. There she led the global commercial strategic direction and long-term planning. As a member of the executive team, she contributed to the corporate strategy and overall governance of the organization. Over an 18-year career at Amgen, Ms. Hamill held a number of executive roles in the US and internationally. Her last role as Senior Vice President and General Manager included overall management of 2,000 employees, the strategic plans and $20 billion in annual revenue for the U.S. Commercial Operations. Ms. Hamill’s areas of therapeutic expertise include inflammation, oncology, gene therapy, nephrology, osteoporosis, cardiovascular disease, migraine, HIV, hepatology, GI and anti-infectives. Since September 2019, Ms. Hamill has served on the board of directors of AnaptysBio, Inc., (Nasdaq: ANAB) a publicly traded clinical-stage antibody-based biotechnology company. Ms. Hamill holds a B.A. in business administration from the University of Arizona.